title: Endoscopic evaluation of low-dose aspirin-induced gastric and duodenal ulcers during prophylaxis with lansoprazole.
abstract: OBJECTIVE
  To compare the endoscopic features of LDA-induced ulcers developing during secondary prophylaxis with lansoprazole (LPZ) and gefarnate (GFN).
  
  
  METHODS
  All ulcers that had developed during prophylaxis with LPZ (15mg once daily) and GFN (50mg twice daily) in a prospective, randomized, double-blind trial, were reviewed and compared by a panel of expert endoscopists, based on endoscopic images available from the trial, to provide evidence for efficacy of LPZ versus GFN in secondary prophylaxis in patients with endoscopically confirmed ulcer scars.
  
  
  RESULTS
  A total of 6 and 53 patients had developed gastric or duodenal ulcers during prophylaxis with LPZ and GFN, respectively. Six gastric ulcers seen in those given LPZ were "small" and "shallow", while, of the 38 gastric ulcers seen those given GFN, 44.7% and 55.3% were "medium" or "large" and "small", respectively. Ulcers associated with blood coagula were seen only in those given GFN. Duodenal ulcers developed in 15 and 0 patients given GFN and LPZ, respectively.
  
  
  CONCLUSIONS
  The ulcers developing during prophylaxis with GFN and LPZ varied in their features. The study findings may be useful when devising a strategy for prophylaxis of ulcers in high-risk patients receiving LDA therapy in a routine clinical setting.
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Sakaki
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Ashida
authors.forename: Yuji
authors.initials: Y
authors.lastname: Mizokami
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Chiba
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Matsui
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Kanto
authors.forename: Naomi
authors.initials: N
authors.lastname: Uemura
authors.forename: Naoki
authors.initials: N
authors.lastname: Hiramatsu
authors.forename: Kentaro
authors.initials: K
authors.lastname: Sugano
mesh_terms: D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001241:Aspirin / Q000009:adverse effects*; D015897:Comorbidity; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000139:chemically induced* / Q000517:prevention & control*; D016099:Endoscopy, Gastrointestinal; D005260:Female; D006801:Humans; D064747:Lansoprazole / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013276:Stomach Ulcer / Q000139:chemically induced* / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D001241:Aspirin